Anti-Myelin-Associated Protein Antibody Development for Stroke

The inhibitory activity associated with myelin is a major barrier to successful axonal regeneration in the adult mammalian central nervous system (CNS). These abundant growth inhibitory molecules include proteoglycans, Nogo-A, myelin-associated glycoprotein (MAG), multifunctional proteoglycan 2, and oligodendrocyte myelin glycoprotein (Omgp). Studies have shown that myelin destruction is usually associated with immunoglobulin and activated complement deposition, which may contribute to autoimmune diseases. After ischemic stroke, MAG, oligomyelin glycoprotein, and Nogo-A are upregulated and contribute to the inhibition of neuronal growth and regeneration. Therefore, these three major inhibitors of neuronal regeneration are important targets for the development of therapeutic antibodies for stroke.

Fig. 1. Vascular repair in the peri-infarct region following stroke in response to VEGF and anti-Nogo-A antibodies. (Rust et al., 2019)

Our Services

As a stroke-focused CRO, Ace Therapeutics offers antibody development services targeting myelin-associated proteins. Our research and development team combines expertise in immunology, neuroscience, and biotechnology to design and optimize monoclonal antibodies targeting myelin-associated proteins. We utilize advanced cell culture techniques, genetic engineering, and antibody characterization analysis to generate high-affinity and specific antibodies with therapeutic potential.

Types of Anti-Myelin-Associated Protein Antibodies We Can Develop

• Anti-Nogo-A antibodies
• Anti-Nogo-66 receptor antibodies
• Anti-MAG antibodies
• Anti-Omgp antibodies

Analysis of Anti-Regenerative Effects of Myelin-Associated Proteins

We can analyze the role of anti-regenerative properties of myelin-associated proteins in experiments, including antibody-mediated targeting of myelin-associated proteins, gene deletion of myelin-associated proteins, blockade of myelin-associated protein receptors, and blockade of downstream messenger kinases in animals. We aim to assist our clients in studying the expression of myelin-associated proteins and their receptors in the ischemic brain to evaluate their potential role in the pathophysiology of stroke.

Effects of Anti-Myelin-Associated Protein Antibody Studies in Stroke Animal Models

We provide well-established animal models of stroke to study the effects of anti-myelin-associated protein antibodies on cortical efferent plasticity and functional recovery in ischemic stroke. Monoclonal antibodies against myelin-associated proteins are administered to animals after stroke and the therapeutic effects are evaluated.

• Functional outcomes measured by the skilled pellet reaching task.
• The Gripping ability of the infarct-contralateral forepaw assessed by the Montoya staircase test.
• Analysis of lesion volume by magnetic resonance imaging.
• Cognitive deficits assessed by the Morris water maze navigation task.
• Orientation tests that measure the animal's response to or away from brief stimuli to assess the degree of neglect and recovery from neglect.

Ace Therapeutics actively pursues partnerships with academic institutions and pharmaceutical companies, leveraging our expertise to help them develop effective therapeutic strategies, including identifying novel targets, and optimizing the properties of anti-myelin-associated protein antibodies. We adhere to the highest standards of safety and quality assurance at all stages of anti-myelin-associated protein antibody development. If you are interested in our services, please do not hesitate to contact us!

1. Rust, R., et al. (2019). Anti-Nogo-A antibodies prevent vascular leakage and act as pro-angiogenic factors following stroke. Scientific reports, 9(1), 20040.